A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.”
This study was published in the June 8, 2011 Nature [I.F >35] by Prof. Stoffel M, Trajkovski M and others from the he Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: AntagomiR-based treatment for T2D: MiRNA-18a decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1 . This study suggests that MiRNA-18a, by down regulating its target gene, it may up regulate the regulator of insulin receptor, caveolin-1. Together, this study suggests that pharmacological formulations encompassing “Anti-MiRNA-18a” may be used in the treatment of NIDDM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., AntagomiR-based treatment for T2D: MiRNA-18a decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1, Genome-2-Bio-Medicine Discovery center (GBMD), 18/08/2014, 07.13 am, http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
